|Awarded On||November 19, 2014|
|Title||Genetic engineering of T cells as an “off-the-shelf” therapy for leukemias and lymphomas|
|Award Mechanism||Bridging the Gap: Early Translational Research Awards|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Laurence Cooper|
|Cancer Sites||Leukemia, Lymphoma|
T cells are a part of the immune system responsible for attacking and destroying tumor cells. Patient-specific cells can be manipulated in the laboratory to redefine specificity and improve potency. This is achieved by combining gene therapy with immunotherapy. However, these laboratory procedures take time during which the patient’s underlying medical condition can deteriorate robbing them of the chance to receive immunotherapy.
Therefore, we developed an approach whereby gene therapy can be used to manipulate T cells before a patient needs them. These T cells can then be frozen in banks and thawed and infused when the patient requires, rather than when the cells are available. This CPRIT a...